Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a corticosteroid and long-acting beta-2 agonist indicated for the treatment of asthma and COPD.
The Propeller platform includes a sensor that is attached to the inhaler. The sensor delivers insights on medication use to a smartphone app, which can then be shared with clinicians to help inform treatment plans.
In a study evaluating the real-world effectiveness of the Propeller platform, asthma patients who monitored their short-acting beta-agonist (SABA) use with the digital tool (received feedback from the system) significantly reduced SABA use, when compared with routine care (no feedback). Moreover, the proportion of days in which patients were SABA-free increased by 21% in the Propeller group, compared with a 17% increase in the routine care group.
“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” said David Van Sickle, co-founder and CEO of Propeller Health. “This is an important step in transforming the way people receive preventative care, enabling self-management from home and ensuring that providers have the bandwidth to focus on high-risk patients.”
In addition to Symbicort, the Propeller platform has also been cleared for use with inhalers manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, as well as many generic equivalent inhalers.
For more information visit propellerhealth.com.
